Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
JNJ Stock Chart & Stats
$218.21
-$4.08(-2.79%)
At close: 4:00 PM EST
$218.21
-$4.08(-2.79%)
Day’s Range― - ―
52-Week Range$141.50 - $228.57
Previous CloseN/A
Volume3.80M
Average Volume (3M)7.88M
Market Cap
$540.74B
Enterprise Value$576.21B
Total Cash (Recent Filing)$18.56B
Total Debt (Recent Filing)$45.80B
Price to Earnings (P/E)20.3
Beta0.11
Next Earnings
Apr 14, 2026EPS Estimate
2.67Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)2.46
Shares Outstanding2,409,295,200
10 Day Avg. Volume9,753,462
30 Day Avg. Volume7,883,575
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.83
Price to Sales (P/S)3.88
P/FCF Ratio17.39
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue6.25
Enterprise Value/Gross Profit9.19
Enterprise Value/Ebitda14.57
Forecast
1Y Price Target
$241.25Price Target Upside10.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)11.55
Revenue Forecast (FY)$100.07B
Bulls Say, Bears Say
Bulls Say
Analyst Upgrades And Revenue OutlookAnalyst upgrades and higher price targets reflect raised revenue and earnings estimates driven by expected sales from a broad new product cycle.
Clinical Trial EfficacyMajesTEC-3 results showing improved progression‑free survival and response rates for Tecvayli plus Darzalex suggest potential expansion into earlier treatment lines and stronger market opportunity for the combination.
Regulatory Clarity And Investor ConfidenceResolution of key biopharma negotiation uncertainty and positive conference takeaways reduced a sector overhang and improved confidence in the company’s forward growth outlook.
Bears Say
Litigation ExposureOngoing talc litigation developments present directional downside with unclear potential for material legal costs that could pressure results if exposure increases.
Safety And Adoption RiskHigher rates of serious infections observed with Tecvayli plus Darzalex, including early infection‑related deaths before enhanced infection management, may slow clinical adoption and prompt additional safety measures.
Valuation RiskLimited scope for further valuation multiple expansion constrains upside from rerating and could cap total return if operational growth falls short of expectations.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $141.50 and its highest was $228.57 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $540.74B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Apr 14, 2026 which is in 75 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jan 21, 2026. The company reported $2.46 earnings per share for the quarter, missing the consensus estimate of $2.463 by -$0.003.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.67.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,295,200 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.46 in its last earnings report, missing expectations of $2.463. Following the earnings report the stock price went down -0.092%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$241.25 (10.56% Upside)
$241.25 (10.56% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 491.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ Company Deck
JNJ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.View all JNJ earnings summariesJNJ Sales Breakdown
64.13% Innovative Medicine
35.87% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$241.25
▲(10.56% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
18.06% Mutual Funds
0.28% Other Institutional Investors
59.59% Public Companies and Individual Investors